.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 021527

« Back to Dashboard
NDA 021527 describes ATROVENT HFA, which is a drug marketed by Boehringer Ingelheim and is included in one NDA. It is available from three suppliers. There are three patents protecting this drug. Additional details are available on the ATROVENT HFA profile page.

The generic ingredient in ATROVENT HFA is ipratropium bromide. There are seven drug master file entries for this compound. Twenty-one suppliers are listed for this compound. Additional details are available on the ipratropium bromide profile page.

Summary for NDA: 021527

Tradename:
ATROVENT HFA
Applicant:
Boehringer Ingelheim
Ingredient:
ipratropium bromide
Patents:3
Therapeutic Class:Respiratory Tract Agents
Formulation / Manufacturing:see details

Pharmacology for NDA: 021527

Mechanism of ActionCholinergic Antagonists

Suppliers and Packaging for NDA: 021527

Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
ATROVENT HFA
ipratropium bromide
AEROSOL, METERED;INHALATION 021527 NDA Boehringer Ingelheim Pharmaceuticals Inc. 0597-0087 0597-0087-17 1 CANISTER in 1 CARTON (0597-0087-17) > 200 AEROSOL, METERED in 1 CANISTER
ATROVENT HFA
ipratropium bromide
AEROSOL, METERED;INHALATION 021527 NDA A-S Medication Solutions 50090-0961 50090-0961-0 1 CANISTER in 1 CARTON (50090-0961-0) > 200 AEROSOL, METERED in 1 CANISTER

Summary for product number 001

Active Rx/OTC/Discontinued:RXDosage:AEROSOL, METERED;INHALATIONStrength0.021MG/INH
Approval Date:Nov 27, 2004TE:RLD:Yes
Patent:6,739,333Patent Expiration:May 26, 2020Product Flag?YSubstance Flag?Delist Request?
Patent:6,983,743Patent Expiration:May 26, 2020Product Flag?YSubstance Flag?Delist Request?
Patent:8,474,447Patent Expiration:Jan 17, 2030Product Flag?YSubstance Flag?Delist Request?

Expired Orange Book Patents for NDA: 021527

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Boehringer Ingelheim
ATROVENT HFA
ipratropium bromide
AEROSOL, METERED;INHALATION021527-001Nov 27, 20045,676,930► subscribe
Boehringer Ingelheim
ATROVENT HFA
ipratropium bromide
AEROSOL, METERED;INHALATION021527-001Nov 27, 20045,766,573► subscribe
Boehringer Ingelheim
ATROVENT HFA
ipratropium bromide
AEROSOL, METERED;INHALATION021527-001Nov 27, 20045,695,743► subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.



Complete Access Available with Subscription
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc